PortfoliosLab logoPortfoliosLab logo
CCCC vs. SOGP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CCCC vs. SOGP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in C4 Therapeutics, Inc. (CCCC) and Lizhi Inc (SOGP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CCCC achieves a 87.43% return, which is significantly higher than SOGP's -6.75% return.


CCCC

1D
-2.98%
1M
-13.73%
6M
60.54%
YTD
87.43%
1Y
54.31%
3Y*
-1.27%
5Y*
-38.34%
10Y*
ALL TIME*
-29.25%

SOGP

1D
-0.51%
1M
-15.27%
6M
-19.68%
YTD
-6.75%
1Y
125.69%
3Y*
13.24%
5Y*
-27.24%
10Y*
ALL TIME*
-29.41%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CCCC vs. SOGP - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
CCCC
C4 Therapeutics, Inc.
87.43%-46.94%-36.28%-4.24%-81.68%-2.81%24.55%
SOGP
Lizhi Inc
-6.75%465.48%-20.80%-56.51%-65.95%-52.32%50.97%

Correlation

The correlation between CCCC and SOGP is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Oct 2, 2020

0.20

Fundamentals

Market Cap

CCCC:

$296.52M

SOGP:

$47.23M

Total Revenue (TTM)

CCCC:

$28.71M

SOGP:

CN¥2.07B

Gross Profit (TTM)

CCCC:

$26.90M

SOGP:

CN¥585.38M

EBITDA (TTM)

CCCC:

-$107.31M

SOGP:

-CN¥138.59M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CCCC vs. SOGP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CCCC
CCCC Risk / Return Rank: 6868
Overall Rank
CCCC Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
CCCC Sortino Ratio Rank: 7474
Sortino Ratio Rank
CCCC Omega Ratio Rank: 6868
Omega Ratio Rank
CCCC Calmar Ratio Rank: 6868
Calmar Ratio Rank
CCCC Martin Ratio Rank: 6565
Martin Ratio Rank

SOGP
SOGP Risk / Return Rank: 8080
Overall Rank
SOGP Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
SOGP Sortino Ratio Rank: 9797
Sortino Ratio Rank
SOGP Omega Ratio Rank: 9595
Omega Ratio Rank
SOGP Calmar Ratio Rank: 7777
Calmar Ratio Rank
SOGP Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CCCC vs. SOGP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for C4 Therapeutics, Inc. (CCCC) and Lizhi Inc (SOGP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CCCCSOGPDifference
Sharpe ratioReturn per unit of total volatility

+0.09

Sortino ratioReturn per unit of downside risk

-2.25

Omega ratioGain probability vs. loss probability

1.18

1.46

-0.28

Calmar ratioReturn relative to maximum drawdown

1.05

1.79

-0.74

Martin ratioReturn relative to average drawdown

2.02

2.33

-0.31

CCCC vs. SOGP - Sharpe Ratio Comparison

The current CCCC Sharpe Ratio is 0.56, which is comparable to the SOGP Sharpe Ratio of 0.47. The chart below compares the historical Sharpe Ratios of CCCC and SOGP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CCCC vs. SOGP - Drawdown Comparison

The maximum CCCC drawdown since its inception was -97.82%, roughly equal to the maximum SOGP drawdown of -99.25%. Use the drawdown chart below to compare losses from any high point for CCCC and SOGP.


Loading charts...

Drawdown Indicators


CCCCSOGPDifference

Max Drawdown

Largest peak-to-trough decline

-97.82%

-99.25%

+1.43%

Max Drawdown (1Y)

Largest decline over 1 year

-52.10%

-70.70%

+18.60%

Max Drawdown (3Y)

Largest decline over 3 years

-90.00%

-86.52%

-3.48%

Max Drawdown (5Y)

Largest decline over 5 years

-97.82%

-97.76%

-0.06%

Current Drawdown

Current decline from peak

-92.91%

-92.77%

-0.14%

Average Drawdown

Average peak-to-trough decline

-72.27%

-84.45%

+12.18%

Ulcer Index

Depth and duration of drawdowns from previous peaks

26.97%

54.11%

-27.14%

Volatility

CCCC vs. SOGP - Volatility Comparison

C4 Therapeutics, Inc. (CCCC) and Lizhi Inc (SOGP) have volatilities of 18.63% and 18.83%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CCCCSOGPDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.63%

18.83%

-0.20%

Volatility (6M)

Calculated over the trailing 6-month period

63.37%

48.10%

+15.27%

Volatility (1Y)

Calculated over the trailing 1-year period

97.27%

269.77%

-172.50%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

117.72%

156.40%

-38.68%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

112.34%

159.50%

-47.16%

Dividends

CCCC vs. SOGP - Dividend Comparison

CCCC has not paid dividends to shareholders, while SOGP's dividend yield for the trailing twelve months is around 21.91%.


PositionTTM2025
CCCC
C4 Therapeutics, Inc.
0.00%0.00%
SOGP
Lizhi Inc
21.91%8.61%

Financials

CCCC vs. SOGP - Financials Comparison

This section allows you to compare key financial metrics between C4 Therapeutics, Inc. and Lizhi Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M600.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
422.82M
(CCCC) Total Revenue
(SOGP) Total Revenue
Please note, different currencies. CCCC values in USD, SOGP values in CNY

Frequently Asked Questions


CCCC and SOGP have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SOGP has higher volatility (18.83%) compared to CCCC (18.63%). In terms of maximum drawdown, CCCC dropped -97.82% vs SOGP's -99.25%.

CCCC currently has the higher Sharpe Ratio (0.56 vs 0.47), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CCCC and SOGP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer